Template:Moexipril: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
===''Moexipril''=== | ===''Moexipril''=== | ||
* [[Moexipril tablet]] | * [[Moexipril tablet]]<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MOEXIPRIL HYDROCHLORIDE TABLET [APOTEX CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d18108f5-98ca-1220-d145-bcf4e71ceaee#nlm34068-7 | publisher = | date = | accessdate = 15 April 2014 }}</ref> | ||
===''Moexipril and Hydrochlorothiazide tablet''=== | ===''Moexipril and Hydrochlorothiazide tablet''=== | ||
* [[Moexipril and Hydrochlorothiazide tablet]] | * [[Moexipril and Hydrochlorothiazide tablet]]<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE TABLET, FILM COATED [TEVA PHARMACEUTICALS USA INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=621614de-4a5c-43c8-af77-e98128f01c8b#nlm34071-1 | publisher = | date = | accessdate = 15 April 2014 }}</ref> | ||
==Overview== | ==Overview== | ||
Revision as of 15:42, 15 April 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2], Amr Marawan, M.D. [3]
Moexipril
Moexipril and Hydrochlorothiazide tablet
Overview
Moexipril tablet is an angiontensin converting enzyme inhibitor drug that is FDA approved for the treatment of hypertension, heart failure, left ventricular dysfunction after myocardial infarction, diabetic nephropathy. Adverse reactions include hypotension, rash, hyperkalemia, disorder of taste, cough. hypotension, rash, hyperkalemia, disorder of taste, cough.
Category
Antihypertensive Agents, Angiotensin Converting Enzyme Inhibitors.
- ↑ 1.0 1.1 "MOEXIPRIL HYDROCHLORIDE TABLET [APOTEX CORP.]". Retrieved 15 April 2014.